Advertisement
 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Oncology

   News

 

 Conferences


   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links
   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

 

 Headlines:

 
 

Back to index

Hoelzer Regimen (BFM)

Abstract: Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults.

In a prospective multicenter study, 368 acute lymphoblastic leukemia (ALL) patients aged 15 to 65 years were treated with an intensified induction and reinduction regimen; 272 (73.9%) achieved complete remission (CR). The median remission duration (MRD) is 24.3 months, and the probability of being in continuous CR (CCR) at greater than 5 years is .37. The median survival for all 368 patients is 27.5 months, and the probability of being alive at 5 years is .39. For the 272 patients in remission the median survival is 58.4 months, and the probability of being alive at 5 years is .49. A lower CR rate was seen for patients with bleeding at diagnosis or with splenomegaly/hepatosplenomegaly. The prognostic factors unfavorable for remission duration were time to CR greater than 4 weeks v less than 4 weeks (P = .0002), age greater than 35 years v less than 35 years (P = .0008), leukocyte count greater than 30,000/microL v less than 30,000/microL (P = .0112), and null ALL v common ALL (c-ALL)/T cell ALL (T-ALL) (P = .05). The remission duration correlated strongly (P = .0001) with the number of these independent prognostic factors. In patients with none of these adverse factors the MRD has not yet been reached, with one adverse factor the MRD is 21.9 months, and with two or three adverse factors the MRD is only 9.6 months. For the immunologic subtype T-ALL, the probability of being in CCR at greater than 5 years is .55; for c-ALL, .34; and for null ALL, .24. According to these results, patients were stratified into a low-risk group with a CCR rate of .62 and a high-risk group with a CCR rate of .28, with the latter now allocated to either further chemotherapy or bone marrow transplantation in first remission.

References

Hoelzer D, Thiel E, Loffler H, Buchner T, Ganser A, Heil G, Koch P, Freund M, Diedrich H, Ruhl H, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988; 71:123 - 131

advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application


Regimen

Induction - Phase I

  • Vincristine 2 mg IV days 1,8,15,22
  • Daunorubicin 25 mg / M2 IV days 1,8,15,22
  • Prednisone 60 mg / M2 PO days 1 - 28
  • L - asparaginase 5,000 units / M2 IV days 1 - 14

Induction - Phase II

  • Cyclophosphamide 650 mg / M2 IV days 29,43,57 maximum dose 1000 mg
  • Ara - C 75 mg / M2 IV days 31 - 34,38 - 41, 45 - 48, 52 - 55
  • 6 - Mercaptopurine 60 mg / M2 PO days 29 - 57

CNS Prophylaxis -- weeks 5 - 8

  • Methotrexate 10 mg / M2 IT days 31,38,45,52 maximum dose is 15 mg
  • Cranial radiotherapy 1800 - 2400 cGy given with phase II induction radiotherapy

Consolidation - Phase I -- begins week 20

  • Vincristine 2 mg IV days 1,8,15,22
  • Doxorubicin 25 mg / M2 IV days 1,8,15,22
  • Dexamethasone 10 mg / M2 PO days 1 - 28

Consolidation -- Phase II

  • Cyclophosphamide 650 mg / M2 IV day 29 maximum dose is 1000 mg
  • Ara - C 75 mg / M2 IV days 31 - 34,38 - 41
  • 6 - Thioguanine 60 mg / M2 PO days 29 - 42

Maintenance

  • 6 - Mercaptopurine 60 mg / M2 PO  daily weeks 10 - 18,29 - 130
  • Methotrexate 20 mg / M2 PO / IV weekly weeks 10 - 18,29 - 130

     
  Summary  
  Complete Response Rate 73.9%
  Median Remission Duration 24.3 months
  Median Survival 27.5 months
  Toxicity  
     

Article reviewed by:

Dr. Tamer Fouad, M.D.

 

 advertisement.gif (61x7 -- 0 bytes)

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright 2001-2012 DoctorsLounge. All rights reserved.